Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 30, 2025
Daily News
June 30, 2025
- J-TEC Targets 1,000 Knee OA Cases Per Year for JACC: CEO
June 30, 2025
- LDP’s Furukawa Vows Policy Support for Domestic Innovation in New Modalities
June 30, 2025
- Rakuten, Taiwan’s Orient EuroPharma Ink Photoimmunotherapy Deal
June 30, 2025
- MOF Poised to Discuss Use of CEA System with MHLW: Budget Examiner
June 30, 2025
- Asahi Kasei Kicks Off Japan PIII for Recomodulin for CIPN
June 30, 2025
- Japan Embraces New AML Era with Tibsovo Debut, Says Hematologist
June 30, 2025
- Moderna Japan Files Updated COVID Shot for Age 11 and Under
June 30, 2025
- LP.8.1-Adapted Novavax COVID Vaccine Filed in Japan: Takeda
June 30, 2025
- Japan Hands Out Orphan Tags to Ultragenyx’s Setrusumab and Lots More
June 30, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…